Digital Mental Health Pioneer Secures $23.7M to Transform Care Access
February 21, 2026, 4:07 pm
Location: United States, California, San Francisco
Employees: 1-10
Founded date: 2019
Big Health raised $23.7 million. This funding will scale its FDA-cleared digital mental health treatments. SleepioRx targets insomnia. DaylightRx addresses generalized anxiety. A recent Centers for Medicare & Medicaid Services policy change now enables national Medicare reimbursement. This key development accelerates the integration of evidence-based digital therapies into routine clinical practice. Big Health plans to deepen provider partnerships. The goal is expanding access across health systems and payer networks. This investment signals growing institutional confidence in digital mental health solutions. It fills critical gaps in mental healthcare access. The company supports over 750,000 individuals. Clinical studies confirm high efficacy rates for both products.
Big Health, a leader in digital mental health, announced a significant funding round. The San Francisco-based company secured $23.7 million. This strategic investment aims to accelerate access to its FDA-cleared solutions. Digital treatments for mental health are gaining traction. This capital injection underscores that trend.
The funding round saw strong backing. .406 Ventures and AlleyCorp co-led the investment. Major participants included CVS Health Ventures, Blue Venture Fund, Sandbox Clinical Ventures, Gilde Healthcare, and Supermoon Capital. These investors recognize the transformative potential of digital therapeutics. They see a clear path for market expansion.
Big Health develops prescription digital therapeutics. These target common mental health conditions. Its flagship products are widely recognized. SleepioRx treats insomnia disorder. DaylightRx addresses generalized anxiety disorder (GAD). Both therapies hold critical FDA clearance. This distinction sets them apart from general wellness applications.
FDA clearance establishes stringent regulatory standards. It ensures safety, efficacy, and clinical validation. This process involves rigorous testing. It mirrors the scrutiny for traditional pharmaceutical treatments. These digital tools are backed by extensive evidence. Randomized controlled trials and real-world data support their effectiveness. They are also recommended in leading clinical guidelines. The American College of Physicians and the National Institute for Health and Care Excellence endorse them.
A pivotal policy shift catalyzed this funding. The Centers for Medicare & Medicaid Services (CMS) introduced new G-codes. These came within the 2025 Physician Fee Schedule. This action established the first national Medicare reimbursement pathway. It marks a monumental step for FDA-cleared digital mental health treatments. Years of fragmented coverage now give way to a unified system.
The CMS policy change will reshape healthcare delivery. It accelerates the integration of evidence-based digital therapeutics. These will move into mainstream clinical workflows. Providers can now offer proven, safe, and effective digital treatments. They will receive reimbursement similar to traditional care. This removes a significant barrier to adoption.
The demand for scalable mental health solutions remains high. Anxiety disorders affect nearly 20 percent of U.S. adults. Close to one-third report persistent insomnia or sleep difficulties. These conditions are widespread. Yet, they often go underdiagnosed and undertreated. Provider shortages are a significant factor. Limited access to behavioral health specialists exacerbates the problem.
Digital therapeutics offer a powerful solution. They bridge the gap between need and access. These treatments deliver care directly to patients. They bypass traditional wait times. They overcome geographic limitations. This approach expands access dramatically.
Big Health has made substantial impact. The company reports supporting over 750,000 individuals to date. Clinical studies confirm high efficacy rates. Up to 76 percent of SleepioRx patients achieve improvement in insomnia. Similarly, 71 percent of DaylightRx patients experience improvement in GAD. These outcomes demonstrate strong clinical value.
The new capital will fuel commercialization efforts. It will deepen provider partnerships. The goal is to expand access across health systems and payer networks. Big Health aims for broad integration. Its solutions can become routine components of mental health care.
Early adoption is already underway. Major health systems recognize the value. Henry Ford Health and Northwell Health have partnered with Big Health. They deploy its digital treatments at scale. This signals growing institutional confidence. Reimbursable digital mental health solutions are gaining trust. They offer a financially viable path to improved patient outcomes.
The investment reflects a belief in validated, first-line digital treatments. Clear reimbursement and predictable economics are key. These solutions can meaningfully improve lives. They can also reduce avoidable healthcare costs. They offer a superior alternative to some current approaches.
This funding round represents more than just financial growth. It signifies a maturation of the digital health sector. Policy makers, investors, and health systems now align. They see the potential for technology to solve urgent healthcare challenges. Big Health stands at the forefront of this transformation. Its mission to expand access to care becomes more attainable. The future of mental health treatment looks increasingly digital. This investment paves the way for wider adoption and better patient outcomes.
Big Health, a leader in digital mental health, announced a significant funding round. The San Francisco-based company secured $23.7 million. This strategic investment aims to accelerate access to its FDA-cleared solutions. Digital treatments for mental health are gaining traction. This capital injection underscores that trend.
The funding round saw strong backing. .406 Ventures and AlleyCorp co-led the investment. Major participants included CVS Health Ventures, Blue Venture Fund, Sandbox Clinical Ventures, Gilde Healthcare, and Supermoon Capital. These investors recognize the transformative potential of digital therapeutics. They see a clear path for market expansion.
Big Health develops prescription digital therapeutics. These target common mental health conditions. Its flagship products are widely recognized. SleepioRx treats insomnia disorder. DaylightRx addresses generalized anxiety disorder (GAD). Both therapies hold critical FDA clearance. This distinction sets them apart from general wellness applications.
FDA clearance establishes stringent regulatory standards. It ensures safety, efficacy, and clinical validation. This process involves rigorous testing. It mirrors the scrutiny for traditional pharmaceutical treatments. These digital tools are backed by extensive evidence. Randomized controlled trials and real-world data support their effectiveness. They are also recommended in leading clinical guidelines. The American College of Physicians and the National Institute for Health and Care Excellence endorse them.
A pivotal policy shift catalyzed this funding. The Centers for Medicare & Medicaid Services (CMS) introduced new G-codes. These came within the 2025 Physician Fee Schedule. This action established the first national Medicare reimbursement pathway. It marks a monumental step for FDA-cleared digital mental health treatments. Years of fragmented coverage now give way to a unified system.
The CMS policy change will reshape healthcare delivery. It accelerates the integration of evidence-based digital therapeutics. These will move into mainstream clinical workflows. Providers can now offer proven, safe, and effective digital treatments. They will receive reimbursement similar to traditional care. This removes a significant barrier to adoption.
The demand for scalable mental health solutions remains high. Anxiety disorders affect nearly 20 percent of U.S. adults. Close to one-third report persistent insomnia or sleep difficulties. These conditions are widespread. Yet, they often go underdiagnosed and undertreated. Provider shortages are a significant factor. Limited access to behavioral health specialists exacerbates the problem.
Digital therapeutics offer a powerful solution. They bridge the gap between need and access. These treatments deliver care directly to patients. They bypass traditional wait times. They overcome geographic limitations. This approach expands access dramatically.
Big Health has made substantial impact. The company reports supporting over 750,000 individuals to date. Clinical studies confirm high efficacy rates. Up to 76 percent of SleepioRx patients achieve improvement in insomnia. Similarly, 71 percent of DaylightRx patients experience improvement in GAD. These outcomes demonstrate strong clinical value.
The new capital will fuel commercialization efforts. It will deepen provider partnerships. The goal is to expand access across health systems and payer networks. Big Health aims for broad integration. Its solutions can become routine components of mental health care.
Early adoption is already underway. Major health systems recognize the value. Henry Ford Health and Northwell Health have partnered with Big Health. They deploy its digital treatments at scale. This signals growing institutional confidence. Reimbursable digital mental health solutions are gaining trust. They offer a financially viable path to improved patient outcomes.
The investment reflects a belief in validated, first-line digital treatments. Clear reimbursement and predictable economics are key. These solutions can meaningfully improve lives. They can also reduce avoidable healthcare costs. They offer a superior alternative to some current approaches.
This funding round represents more than just financial growth. It signifies a maturation of the digital health sector. Policy makers, investors, and health systems now align. They see the potential for technology to solve urgent healthcare challenges. Big Health stands at the forefront of this transformation. Its mission to expand access to care becomes more attainable. The future of mental health treatment looks increasingly digital. This investment paves the way for wider adoption and better patient outcomes.